BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...
Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received breakthrough devices...
Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline
According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)...
Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation
On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...
Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that it has received...
Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales
US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...
Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...
Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...
Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...
Humanwell Healthcare Receives NMPA Approval for HW241045 IPF Clinical Trials
China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation...
Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy
China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...
CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...
Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China
Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...
ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D
Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...
Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01
China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...
Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu
Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...
Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors
China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...
Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China
China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...
Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau
On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...
Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials
China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...